Brief: Oncolytics Doses First Patient In Phase 2 IRENE Study Evaluating Pelareorep-Anti-PD-1 Combination Treatment
26/08/2020 12:07
Aug 26 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® DOSES FIRST PATIENT IN PHASE 2 IRENE
STUDY
EVALUATING PELAREOREP-ANTI-PD-1 COMBINATION TREATMENT IN
TRIPLE-NEGATIVE BREAST CANCER
Source text for Eikon: ID:nCNWHZSFDa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer